Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 05/26/23 01:30:00 on US and Canada Markets.
Presentations include new data further demonstrating the immune responses induced by TG4001 and recently updated results from the adjuvant Phase I trial of neoantigen vaccine TG4050 in head and neck cancer Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that desi...
Presentations include new data further demonstrating the immune responses induced by TG4001 and recently updated results from the adjuvant Phase I trial of neoantigen vaccine TG4050 in head and neck cancer Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that desi...
GENEVA, SWITZERLAND / ACCESSWIRE / May 26, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFFD )(OTCQB: RLFTD ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to b...
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma TOKYO, May 26, 2023 - (JCN Newswire) - Eisai and Merck & Co., Inc., Rahway, NJ, USA (known...
The ‘Coming To A Storm Near You’ launch was the second of two dedicated Electron launches to deploy a constellation of hurricane monitoring satellites for NASA Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a leading launch...
SAR’579/IPH6101, ANKET ® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi Preliminary data published show SAR’579 was ...
SAR’579/IPH6101, ANKET ® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi Preliminary data published show SAR’579 was ...
– If Granted by the European Commission, Veklury will become the First and Only Authorized Antiviral Treatment Across All Stages of Renal Disease – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Brisbane, Australia (ABN Newswire) - North American lithium producer Sayona Mining Limited (ASX:SYA) (FRA:DML) (OTCMKTS:SYAXF) has secured additional funding to speed development of its Quebec lithium resources, with the launch of a fully underwritten A$200 million two tranche placement (Placemen...
Brisbane, Australia (ABN Newswire) - North American lithium producer Sayona Mining Limited (ASX:SYA) (FRA:DML) (OTCMKTS:SYAXF) has secured additional funding to speed development of its Quebec lithium resources, with the launch of a fully underwritten A$200 million two tranche placement (Placemen...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
11.81%Change Percent:
Confluent Inc. Company Name:
CFLT Stock Symbol:
NASDAQ Market:
confluent.io Website: